MONDAY, May 8, 2017 -- The first new drug to treat amyotrophic lateral sclerosis (ALS) in more than 20 years has been approved by the U.S. Food and Drug Administration.
Radicava (edaravone) is taken intravenously daily for 14 days, followed by 14 days without the drug. Subsequent treatment cycles consist of treatment for 10 out of 14 days, followed by 14 days without the drug.
WEDNESDAY, March 29, 2017 -- On-the-job exposure to electromagnetic fields may double the risk of developing amyotrophic lateral sclerosis (ALS), a degenerative disease of the nervous system, a new study suggests.
Electric company linemen, welders, sewing machine operators and airplane pilots are all people in occupations that could boost the chances of getting the always-fatal disease, said senior researcher Roel Vermeulen.